Navigation Links
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Date:3/9/2010

hase 2b clinical trial of Empatic.  The results of this trial demonstrated the following:

  • Patients completing 24 weeks of Empatic360 (bupropion SR 360mg/zonisamide SR 360 mg) therapy lost 9.9% of their baseline body weight compared to 1.7% for placebo patients (p<0.001).  Importantly, mean weight loss for patients on Empatic continued to decline through the endpoint of the trial, with no evidence of a weight loss plateau.  
  • Improvements were observed in key markers of cardiometabolic risk, such as waist circumference, triglycerides, fasting insulin and blood pressure, compared to placebo.  
  • The most commonly reported adverse events, as well as those leading to discontinuation, for all Empatic patients were headache, nausea and insomnia.  Adverse events and laboratory findings appeared to be consistent with the individual components of Empatic.  There were no statistically or clinically meaningful differences between Empatic and placebo on measures of cognitive function, depression, suicidality or anxiety.

Corporate

  • In July, the C
    '/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Moms are ready to live the ... and their kids, according to the results of the ... Go Mobile for Moms, the latest installment in BabyCenter,s ... 1 pregnancy and parenting web and mobile destination worldwide, ... moms surveyed say they can,t think of a reason ...
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical ... device received 510 (k) OTC clearance by the U.S. ... 100 to be marketed over the Internet for: ... muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated medical ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... PARSIPPANY, N.J. , Jan. 14 As ... market, the company has announced the addition of three Vice ... these positions bring a deep knowledge of the spine and ... distribution networks in their respective areas.   , Randy ...
... , HORSHAM, Pa. , ... 3 clinical study comparing the efficacy and safety of STELARA™ ... severe plaque psoriasis appear today in The New England ... clinical response with both doses of STELARA than with etanercept ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market ... of facts, figures and forecasts on the global medical ... forecast categories the Worldwide Medical Market Forecasts to ... views on the worldwide medical market to reveal key ... you data for 2010-2019, covering each country market individually, ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... 13 - Global innovation firm frog design today ... team with several new appointments. The new hires ... and building on its strong growth in multiple ... and brand strategy. Previously Creative Director for Nike,s ...
... 13 Genomic Health, Inc. (Nasdaq: GHDX ... Operating and Financial Officer, will present at the Eighth ... Tuesday, May 19, 2009 at 11:00 a.m. PT.To access ... visit the Investor Relations section of Genomic Health,s website ...
... 13 Celator Pharmaceuticals today announced that Scott Jackson, ... 2009 BIO International Convention in Atlanta. Mr. Jackson ... the company,s progress with two ongoing Phase 2 clinical ... (AML) patients and first-relapse AML patients. The presentation ...
... Fla., May 13 Ever since she was 6 years ... years of hard work and education she has her own ... their parents every day who want better health and more ... her new book, "Common Sense Pediatrics" ( published by ...
... Intelligent Charge Capture Emerges as Preferred Technology ... MedAptus(R), market leader for charge capture technologies, ... Physicians (UMP), a premier multi-specialty physician ... for charge capture automation.Founded in 1997 and ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... officer, is scheduled to present a company overview at the ... Wednesday, May 20th at 2:00 p.m. PT.To access the live ... www.rigel.com . Please connect to Rigel,s website several minutes ...
Cached Medicine News:Health News:frog design Strengthens Creative Leadership With New Appointments 2Health News:Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention 2Health News:'Common Sense Pediatrics': Combining Alternative and Traditional Medicine in Everyday Practice 2Health News:University of Minnesota Physicians Chooses MedAptus Following Comprehensive Vendor Review 2Health News:University of Minnesota Physicians Chooses MedAptus Following Comprehensive Vendor Review 3
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Medicine Products: